Unlocking the potential of nanocarrier-mediated mRNA delivery across diverse biomedical frontiers: A comprehensive review

被引:2
作者
Pawar, Smita [1 ]
Pingale, Prashant [2 ]
Garkal, Atul [3 ,4 ,5 ]
Osmani, Riyaz Ali M. [6 ]
Gajbhiye, Kavita [7 ]
Kulkarni, Madhur [8 ]
Pardeshi, Krutika [9 ]
Mehta, Tejal [3 ]
Rajput, Amarjitsing [7 ]
机构
[1] Inst Chem Technol, Dept Pharmaceut Sci & Technol, NP Marg, Mumbai 400019, Maharashtra, India
[2] GESs Sir Dr M S Gosavi Coll Pharmaceut Educ & Res, Dept Pharmaceut, Nasik 422005, Maharashtra, India
[3] Nirma Univ, Inst Pharm, Dept Pharmacol, Ahmadabad 382481, Gujarat, India
[4] Johns Hopkins Univ, Sch Med, Ctr Nanomed, Wilmer Eye Inst, Baltimore, MD 21231 USA
[5] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21231 USA
[6] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmaceut, Mysuru 570015, Karnataka, India
[7] Bharti Vidyapeeth Deemed Univ, Poona Coll Pharm, Dept Pharmaceut, Bharti Vidyapeeth Educ Complex, Pune 411038, Maharashtra, India
[8] SCESs Indira Coll Pharm, New Pune Mumbai Highway, Pune 411033, Maharashtra, India
[9] Sandip Univ, Sch Pharmaceut Sci, Dept Pharmacol, Nasik 422213, Maharashtra, India
关键词
Nanocarriers; mRNA; Gene delivery; Vesicular systems; LIPID NANOPARTICLE FORMULATIONS; SMALL INTERFERING RNA; IN-VIVO; GENE DELIVERY; INTRACELLULAR DELIVERY; SYSTEMIC DELIVERY; CARBON NANOTUBES; DENDRITIC CELLS; SIRNA DELIVERY; POLYMERIC NANOPARTICLES;
D O I
10.1016/j.ijbiomac.2024.131139
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Messenger RNA (mRNA) has gained marvelous attention for managing and preventing various conditions like cancer, Alzheimer's, infectious diseases, etc. Due to the quick development and success of the COVID-19 mRNAbased vaccines, mRNA has recently grown in prominence. A lot of products are in clinical trials and some are already FDA-approved. However, still improvements in line of optimizing stability and delivery, reducing immunogenicity, increasing efficiency, expanding therapeutic applications, scalability and manufacturing, and long-term safety monitoring are needed. The delivery of mRNA via a nanocarrier system gives a synergistic outcome for managing chronic and complicated conditions. The modified nanocarrier-loaded mRNA has excellent potential as a therapeutic strategy. This emerging platform covers a wide range of diseases, recently, several clinical studies are ongoing and numerous publications are coming out every year. Still, many unexplained physical, biological, and technical problems of mRNA for safer human consumption. These complications were addressed with various nanocarrier formulations. This review systematically summarizes the solved problems and applications of nanocarrier-based mRNA delivery. The modified nanocarrier mRNA meaningfully improved mRNA stability and abridged its immunogenicity issues. Furthermore, several strategies were discussed that can be an effective solution in the future for managing complicated diseases.
引用
收藏
页数:25
相关论文
共 297 条
  • [1] Polymeric nanoparticles promote endocytosis of a survivin molecular beacon: Localization and fate of nanoparticles and beacon in human A549 cells
    Adinolfi, Barbara
    Pellegrino, Mario
    Tombelli, Sara
    Trono, Cosimo
    Giannetti, Ambra
    Domenici, Claudio
    Varchi, Greta
    Sotgiu, Giovanna
    Ballestri, Marco
    Baldini, Francesco
    [J]. LIFE SCIENCES, 2018, 215 : 106 - 112
  • [2] Nanostructured lipid carriers of ivermectin as a novel drug delivery system in hydatidosis
    Ahmadpour, Ehsan
    Godrati-Azar, Zahra
    Spotin, Adel
    Norouzi, Roghayeh
    Hamishehkar, Hamed
    Nami, Sanam
    Heydarian, Peyman
    Rajabi, Saba
    Mohammadi, Maryam
    Perez-Cordon, Gregorio
    [J]. PARASITES & VECTORS, 2019, 12 (01)
  • [3] mRNA Lipoplexes with Cationic and Ionizable α-Amino-lipophosphonates: Membrane Fusion, Transfection, mRNA Translation and Conformation
    Akhter, Sohail
    Berchel, Mathieu
    Jaffres, Paul-Alain
    Midoux, Patrick
    Pichon, Chantal
    [J]. PHARMACEUTICS, 2022, 14 (03)
  • [4] The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
    Akinc, Akin
    Maier, Martin A.
    Manoharan, Muthiah
    Fitzgerald, Kevin
    Jayaraman, Muthusamy
    Barros, Scott
    Ansell, Steven
    Du, Xinyao
    Hope, Michael J.
    Madden, Thomas D.
    Mui, Barbara L.
    Semple, Sean C.
    Tam, Ying K.
    Ciufolini, Marco
    Witzigmann, Dominik
    Kulkarni, Jayesh A.
    van der Meel, Roy
    Cullis, Pieter R.
    [J]. NATURE NANOTECHNOLOGY, 2019, 14 (12) : 1084 - 1087
  • [5] Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
    Akinc, Akin
    Querbes, William
    De, Soma
    Qin, June
    Frank-Kamenetsky, Maria
    Jayaprakash, K. Narayanannair
    Jayaraman, Muthusamy
    Rajeev, Kallanthottathil G.
    Cantley, William L.
    Dorkin, J. Robert
    Butler, James S.
    Qin, LiuLiang
    Racie, Timothy
    Sprague, Andrew
    Fava, Eugenio
    Zeigerer, Anja
    Hope, Michael J.
    Zerial, Marino
    Sah, Dinah W. Y.
    Fitzgerald, Kevin
    Tracy, Mark A.
    Manoharan, Muthiah
    Koteliansky, Victor
    de Fougerolles, Antonin
    Maier, Martin A.
    [J]. MOLECULAR THERAPY, 2010, 18 (07) : 1357 - 1364
  • [6] Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines
    Aldosari, Basmah N.
    Alfagih, Iman M.
    Almurshedi, Alanood S.
    [J]. PHARMACEUTICS, 2021, 13 (02) : 1 - 29
  • [7] Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
    Alexopoulou, L
    Holt, AC
    Medzhitov, R
    Flavell, RA
    [J]. NATURE, 2001, 413 (6857) : 732 - 738
  • [8] Liposomal drug delivery systems: From concept to clinical applications
    Allen, Theresa M.
    Cullis, Pieter R.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) : 36 - 48
  • [9] ALLEN TM, 1983, J PHARMACOL EXP THER, V226, P539
  • [10] Stability of mRNA/cationic lipid lipoplexes in human and rat cerebrospinal fluid: Methods and evidence for nonviral mRNA gene delivery to the central nervous system
    Anderson, DM
    Hall, LL
    Ayyalapu, AR
    Irion, VR
    Nantz, MH
    Hecker, JG
    [J]. HUMAN GENE THERAPY, 2003, 14 (03) : 191 - 202